Wickham Laboratories Ltd is delighted to announce our most recent technical article on, “Microbiological Considerations in Cleanroom Validation”, which has been featured in European Pharmaceutical Review’s December 2018 issue.
Microbiological contamination is a major safety concern within the manufacturing and development of all pharmaceutical & medical devices. This article discusses how and why a cleanroom environment plays an important role during these processes.
An excerpt of this article as follows:
CLEANROOMS and other controlled environments play a vital role in manufacturing and…
Boyds, a leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, has set up a Clinical and Medical Affairs Group to provide pharmaceutical medicine and medical monitoring support to its clients and their programmes.
Dr Lalitha Mahadavan has been appointed as Director of Clinical and Medical Affairs and will head up the Cambridge-based Group, which will provide a multi-speciality consulting service to Boyds’ client portfolio.
Lalitha is a Consultant in Pharmaceutical Medicine (GMC Registered) and a Fellow of the Faculty of…
The RSA Group, a leading Life Sciences executive search firm, announced today that Mark Johnson has joined the company as a Partner. Mark is a respected life sciences search professional with particular expertise in the cell and gene therapy sector.
Mark has significant experience across medical, manufacturing and supply chain, commercial, R&D, CMC, Clinical Operations, Regulatory and Programme / Project Leader recruitment. This stems from an early career in biologics development, manufacturing and quality at MedImmune and Novartis. Most recently he has focused on cell and gene therapy…
Cambridge, UK, 04 February 2019: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. (NASDAQ: MRNA) has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta’s Affimer technology for certain collaboration…
Tokyo, Japan and London, UK, 4 February 2019 – Sosei Group Corporation (“the Company”; TSE: 4565), announces it has entered into a structured financing agreement1 with Medicxi, a venture fund dedicated to financing asset-centric companies, to form two independent companies, Orexia Limited (“Orexia”) and Inexia Limited (“Inexia”), that aim to develop novel therapies based on positive modulators of the G protein-coupled receptors Orexin OX1 and OX2 for neurological diseases. Medicxi will be investing in both companies with an aggregate amount of up to €40 million.
Under the terms of…
PRINCETON, NJ – Jan. 29, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 18 of its Simcyp® Population-based Simulator.
“I am delighted to introduce Simcyp Simulator v18, which includes several major modeling and simulation advances to help improve the safety and efficacy of new drugs – both small molecules and biologics – under development,” said Certara’s Simcyp President and Managing Director Steve Toon, PhD.
“When we began developing the Simcyp Simulator 20…
Cambridge and London, UK, 29 January 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK medical research charity, today announced they have entered into a collaboration agreement for an ion channel drug discovery project in the field of neuroscience. The project aims to identify novel selective small molecule modulators of a specific ion channel target, which human patient gene association studies have identified as likely to be involved in neurological pathogenesis.
LifeArc will have responsibility for all new…
Cambridge, UK, 28 January 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing technology, known as base editing. The technology potentially has applications in the development of new cell therapies and will augment Horizon’s research tools and services.
Horizon will collaborate with Rutgers University to further develop the…
The pharma industry has changed dramatically in recent decades, not only in terms of the vast strides that have been made in science, but also in terms of the leadership landscape. In the 1970s, it was highly unlikely that a woman would be running one of the world’s largest pharma companies, and today we have Emma Walmsley at the helm of GlaxoSmithKline.
According to recent studies women in healthcare represent 65% of the workforce – a significantly higher ratio when compared to other key industries (Tech – 26%, Financial Services – 46%). Despite their buying power and workforce influence,…